Triphala for Weight Management

Research suggests that Triphala and its constituent compounds may have some relevance to weight and fat metabolism, though the evidence to date is largely preliminary and indirect. A 2025 laboratory and computational study found that Triphala-derived compounds — particularly ellagic acid and chebulic acid — inhibited pancreatic lipase, an enzyme involved in fat digestion, while a 2024 network pharmacology study identified several Triphala bioactives as potential binders to obesity-related gene targets such as AKT1 and PPARG. A small 2013 clinical trial examining a related Ayurvedic formulation reported modest reductions in body weight, BMI, and blood lipids, though the sample size of 19 patients and limited methodological detail make those findings difficult to interpret with confidence. The available body of evidence consists primarily of computational modeling, animal studies, and small or single-case clinical observations — with no randomized controlled trials specifically focused on Triphala for weight management — meaning that while the mechanistic hypotheses are scientifically plausible, no firm conclusions about effectiveness in humans can yet be drawn.